Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.

Authors:
Etemadifar M; Abhari AP; Nouri H; Eighani N; Salari M and 1 more

Journal:
J Neurol Sci

Publication Year: 2022

DOI:
10.1016/j.jns.2022.120518

PMCID:
PMC9731817

PMID:
36521195

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Neurol Sci

Abbreviation: J Neurol Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Global uncertainty in the diagnosis of neurological complications of SARS-CoV-2 infection by both n…
Tamborska AA; Wood GK; Westenberg E and 27 more (2023) - Transparency Score: 3/6
New cases of dementia are rising in elderly populations in Wales, UK.
Stevenson-Hoare J; Schalkamp AK; Sandor C and 2 more (2023) - Transparency Score: 3/6
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third …
Dreyer-Alster S; Menascu S; Mandel M and 13 more (2022) - Transparency Score: 3/6
COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case…
Germano F; Bellucci M; Grisanti S and 15 more (2022) - Transparency Score: 3/6
Frequency and burden of neurological manifestations upon hospital presentation in COVID-19 patients…
Marcolino MS; Anschau F; Kopittke L and 51 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest None."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025